Efekat ciklofotokoagulacije diodnim laserom na lečenje bolesnika sa refraktornim glaukomom

  • Vladimir Čanadanović Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
  • Ljiljana Tušek-Lješević Klinika za očne bolesti Klinički centar Vojvodine
  • Aleksandar Miljković Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
  • Sava Barišić Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia
  • Tatjana Bedov Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
  • Nikola Babić Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
DOI: https://doi.org/10.2298/5123
Ključne reči: ophthalmologic surgical procedures||, ||hirurgija, oftalmološka, procedure, glaucoma||, ||glaukom, laser coagulation||, ||koagulacija laserom, lasers||, ||laseri, intraocular pressure||, ||intraokularni pritisak, treatment outcome||, ||lečenje, ishod,

Sažetak



Uvod/cilj. Refrakorni glaukom spada u grupu glaukoma koji ne reaguje na konvencionalnu terapiju. Cilj ove studije bio je da se odredi efekat sniženja intraokularnog pritiska (IOP) kod bolesnika sa refraktornim glaukomom nakon transskleralne ciklofotokoagulacije diodnim laserom. Metodi. Ova nerandomizirana, retrospektivna studija obuhvatila je 95 očiju sa refraktornim glaukomom lečenih dioda laser ciklofotokoagulacijom na Klinici za očne bolesti Kliničkog centra Vojvodine u periodu 2007–2012, prema ustanovljenom protokolu (16–18 pečata, 270°, do 5J energije). Simptomi, vidna oštrina i IOP su praćeni 7 dana, a zatim 1, 3 i 6 meseci nakon lečenja. Rezultati. Ukupno 25 bolesnika (95 očiju) bilo je uključeno u studiju, 24 (25,2%) bolesnika sa primarnim (1. grupa) i 71 (74,5%) bolesnik sa sekundarnim (2. grupa)  glaukomom. Srednji IOP pre terapije kod obe grupe bio je sličan: 36,08 ± 8,39 mmHg za prvu i 37,36 ± 8,19 mmHg za drugu grupu. Srednje vrednosti IOP za prvu grupu tokom perioda praćenja bile su: 7. dana 13,96 ± 8,30 mmHg (62,1% sniženja), 30. dana 18,44 ± 8,85 (48,9% sniženja), nakon 3 meseca 22,44 ± 7,36 mmHg (37,8% sniženja), nakon 6 meseci 25,92 ± 7,65 mmHg (28,2% sniženja). Srednje vrednosti IOP za drugu grupu tokom perioda praćenja bile su: 7. dana 15,77 ± 9,73 mmHg (57,8% sniženja), 30. dana 20,14 ± 10,20 mmHg (46,1% sniženja), nakon 3 meseca 23,46 ± 9,83 mmHg (37,2% sniženja), i nakon 6 meseci 27,23 ± 9,87 mmHg (27,2% sniženja). Bol je pre terapije bio prisutan kod 70 (73,6%) bolesnika, a nakon tretmana kod samo 4 (4,2%) bolesnika. Tegobe kao što su pečenje, osećaj stranog tela, bockanje, postoperativno su bile prisutne kod 39 (41%) bolesnika. Posle lečenja, tegobe nisu imala 52 (54,7%) bolesnika. Zaključak. Naša studija je potvrdila da je transskleralna ciklofotokoagulacija diodnim laserom koristan i efikasan metod u smanjenju IOP, što ga čini terapijom izbora za refraktorni glaukom.

Reference

Berlin MS. Miscallenous laser procedures including laser ciliary body therapy. In: Stamper R, Lieberman MF, Drake MV, editors. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. 8th ed. Philadelphia, PA: Mosby-Elsevier; 2009. p. 456−7.

Khalid M, Rafay A, Mirza J, Asim W, Muhammad T, Qazi A. Transscleral Diode Laser Cyclophotocoagulation for the Treatment of Refractory Glaucoma. Pak J Ophthalmol 2007; 23(4): 204−8.

Khomchik OV, Bol'shunov AV, Il'ina TS. Laser cyclodestructive procedures in glaucoma treatment. Vestn Oftalmol 2012; 128(3): 54−9. (Russian)

Subrata M, Ritu G, Jatin A. Diode laser cyclophotocoagulation. J Curr Glaucoma Pract 2009; 3(2):47-59.

van der Zypen E, England C, Fankhauser F, Kwasniewska S. The ef-fect of transscleral laser cyclophotocoagulation on rabbit ciliary body vascularization. Graefes Arch Clin Exp Ophthalmol 1989; 227(2): 172−9.

Schubert HD, Federman JL. A comparison of CW Nd: YAG contact transscleral cyclophotocoagulation with cyclocryopexy. Invest Ophthalmol Vis Sci 1989; 30(3): 536−42.

Liu G, Mizukawa A, Okisaka S. Mechanism of intraocular pressure decrease after contact transscleral continuous-wave Nd:YAG laser cyclophotocoagulation. Ophthalmic Res 1994; 26(2): 65−79.

Hennis HL, Stewart WC. Semiconductor diode laser transscleral cyclophotocoagulation in patients with glaucoma. Am J Oph-thalmol 1992; 113(1): 81−5.

Agarwal HC, Gupta V, Sihota R. Evaluation of contact versus non-contact diode laser cyclophotocoagulation for refractory glaucomas using similar energy settings. Clin Experiment Ophthalmol 2004; 32(1): 33−8.

Cantor LB, Nichols DA, Katz LJ, Moster MR, Poryzees E, Shields JA, et al. Neodymium-YAG transscleral cyclophotocoagulation. The role of pigmentation. Invest Ophthalmol Vis Sci 1989; 30(8): 1834−7.

Schubert HD, Agarwala A, Arbizo V. Changes in aqueous out-flow after in vitro neodymium: yttrium aluminum garnet laser cyclophotocoagulation. Invest Ophthalmol Vis Sci 1990; 31(9): 1834−8.

Morrison J, Pollack I. Cyclodestruction. In: Morisson J, Pollack I, editors. Glaucoma: Science and practice. New York: Thieme; 2003. p. 448−55.

Noureddin BN, Zein W, Haddad C, Ma'luf R, Bashshur Z. Diode laser transcleral cyclophotocoagulation for refractory glauco-ma: a 1 year follow-up of patients treated using an aggressive protocol. Eye (Lond) 2006; 20(3): 329−35.

Murphy CC, Burnett CA, Spry PG, Broadway DC, Diamond JP. A two centre study of the dose-response relation for transscleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol 2003; 87(10): 1252−7.

Mastrobattista JM, Luntz M. Ciliary body ablation: where are we and how did we get here. Surv Ophthalmol 1996; 41(3): 193−213.

Benson MT, Nelson ME. Cyclocryotherapy: a review of cases over a 10-year period. Br J Ophthalmol 1990; 74(2): 103−5.

Schuman JS, Bellows AR, Shingleton BJ, Latina MA, Allingham RR, Belcher CD, et al. Contact transscleral Nd:YAG laser cyclopho-tocoagulation. Ophthalmology 1992; 99(7): 1089−95.

Ulbig MW, McHugh DA, McNaught AI, Hamilton AM. Clinical comparison of semiconductor diode versus neodymium: YAG non-contact cyclo photocoagulation. Br J Ophthalmol 1995; 79(6): 569−74.

Iliev ME, Gerber S. Long-term outcome of trans-scleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Oph-thalmol 2007; 91(12): 1631−5.

Rosentreter A, Gaki S, Lappas A, Cursiefen C, Dietlein TS. Previous cyclodestruction is a risk factor for late-onset hypotony and suprachoroidal haemorrhage after glaucoma drainage device surgery. Br J Ophthalmol 2013; 97(6): 715−9.

Ataullah S, Biswas S, Artes PH, O'Donoghue E, Ridgway AE, Spencer AF. Long term results of diode laser cycloablation in complex glaucoma using the Zeiss Visulas II system. Br J Ophthalmol 2002; 86(1): 39−42.

Hawkins TA, Stewart WC. One-year results of semiconductor transscleral cyclophotocoagulation in patients with glaucoma. Arch Ophthalmol 1993; 111(4): 488−91.

Egbert PR, Fiadoyor S, Budenz DL, Dadzie P, Byrd S. Diode laser transscleral cyclophotocoagulation as a primary surgical treat-ment for primary open-angle glaucoma. Arch Ophthalmol 2001; 119(3): 345−50.

Kosoko O, Gaasterland DE, Pollack IP, Enger CL. Long-term out-come of initial ciliary ablation with contact diode laser trans-scleral cyclophotocoagulation for severe glaucoma. The Diode Laser Ciliary Ablation Study Group. Ophthalmology 1996; 103(8): 1294−302.

Objavljeno
2015/07/08
Broj časopisa
Vol. 72 Br. 1 (2015)
Rubrika
Originalni članak